T. Rowe Price Associates
TNYA icon

T. Rowe Price Associates’s Tenaya Therapeutics TNYA Stock Holding History

T. Rowe Price Associates’s Portfolio TNYA Stock Details TNYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24K Hold
31,453
– – ﹤0.01% 3222
2026
Q1 		$22K Hold
31,453
– – ﹤0.01% 3116
2025
Q4 		$23K Hold
31,453
– – ﹤0.01% 3076
2025
Q3 		$51K Sell
31,453
-36,129
-53% -$36.4K ﹤0.01% 3011
2025
Q2 		$42K Sell
67,582
-21,988
-25% -$11.2K ﹤0.01% 3019
2025
Q1 		$52K Sell
89,570
-46,664
-34% -$46K ﹤0.01% 2923
2024
Q4 		$196K Sell
136,234
-2,892,201
-96% -$6.48M ﹤0.01% 2691
2024
Q3 		$5.84M Sell
3,028,435
-485,289
-14% -$1.37M ﹤0.01% 1252
2024
Q2 		$10.9M Buy
3,513,724
+167,202
+5% +$690K ﹤0.01% 1097
2024
Q1 		$17.5M Sell
3,346,522
-1,198,021
-26% -$5.73M ﹤0.01% 1007
2023
Q4 		$14.7M Buy
4,544,543
+69,377
+2% +$150K ﹤0.01% 1019
2023
Q3 		$11.4M Buy
4,475,166
+5,525
+0.1% +$23.1K ﹤0.01% 1053
2023
Q2 		$26.2M Buy
4,469,641
+82,858
+2% +$482K ﹤0.01% 863
2023
Q1 		$12.5M Sell
4,386,783
-85,419
-2% -$240K ﹤0.01% 1018
2022
Q4 		$8.99M Buy
4,472,202
+2,357,950
+112% +$5.76M ﹤0.01% 1071
2022
Q3 		$6.13M Sell
2,114,252
-1,252,528
-37% -$5.85M ﹤0.01% 1164
2022
Q2 		$19M Buy
3,366,780
+335,378
+11% +$2.71M ﹤0.01% 1182
2022
Q1 		$35.7M Buy
3,031,402
+37,899
+1% +$459K ﹤0.01% 1076
2021
Q4 		$55.6M Buy
2,993,503
+220,394
+8% +$4.8M 0.01% 962
2021
Q3 		$56M Buy
+2,773,109
New +$59.6M 0.01% 967

Other funds holding TNYA

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.77B AUM 65.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates's TNYA Position: Q2 2026 in Review

T. Rowe Price Associates held its Tenaya Therapeutics (TNYA) position steady in Q2 2026 at 31,453 shares worth $24K. The position accounts for ﹤0.01% of the portfolio, ranked #3222.

T. Rowe Price Associates first reported a position in TNYA in Q3 2021 and has held it in 20 quarters since. The position peaked at $56M in Q3 2021. 101 funds tracked by Wall St. Rank hold TNYA as of Q2 2026.

  • T. Rowe Price Associates held 31,453 shares of Tenaya Therapeutics worth $24K as of Q2 2026.
  • T. Rowe Price Associates left its Tenaya Therapeutics share count unchanged in Q2 2026.
  • Tenaya Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #3222 holding.
  • T. Rowe Price Associates first reported a position in Tenaya Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • T. Rowe Price Associates's Tenaya Therapeutics position peaked at $56M in Q3 2021.
  • 101 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.